OZYMF Stock Chart & Stats
$90.00
$0.00(0.00%)
At close: 4:00 PM EST
$90.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$90.00 - $91.00
Previous CloseN/A
Volume3.00
Average Volume (3M)0.00
Market Cap
$4.39M
Enterprise Value$26.44M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.00
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,712
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap6.02
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OZYMF FAQ
What was Orphazyme’s price range in the past 12 months?
Orphazyme lowest stock price was $90.00 and its highest was $91.00 in the past 12 months.
What is Orphazyme’s market cap?
Orphazyme’s market cap is $4.39M.
When is Orphazyme’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Orphazyme’s earnings last quarter?
Currently, no data Available
Is Orphazyme overvalued?
According to Wall Street analysts Orphazyme’s price is currently Overvalued.
Does Orphazyme pay dividends?
Orphazyme does not currently pay dividends.
What is Orphazyme’s EPS estimate?
Orphazyme’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Orphazyme have?
Orphazyme has 41,712 shares outstanding.
What happened to Orphazyme’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Orphazyme?
Currently, no hedge funds are holding shares in OZYMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orphazyme
Strategic Partners A/S currently conducts minimal business operations. Its previous activities centered on the field of biotechnology. The firm, originally known as Orphazyme A/S, adopted the new moniker Strategic Partners A/S in October 2024. Established in 2009, the company's base of operations is situated in Herlev, Denmark.
Technical Analysis
Achieve Life Sciences
―
Avalo Therapeutics
―
Corbus Pharmaceuticals
―
Genprex
―
Opus Genetics
―
Bioxcel Therapeutics
―